TIMP1 and ovarian carcinoma: Some studies failed to demonstrate an impact of TIMP1 tissue levels on ovarian cancer survival rates [35,36], while others described elevated pre-operative or post-chemotherapy serum levels associated with unfavorable clinical outcomes [34,37].